Challenge

Our client Heel leading manufacturer of homeopathic medicinal products dedicated in research, dealt with a non-suitable regulatory environment. Existing requirements as applied by national authorities did not honor investments in scientific research. Alber & Geiger faced a European Commission reluctant for legislative changes and differing Member State approaches.

Strategy

The strategy co-ordinated legal, ethical, medical and scientific concepts into coherent arguments. It showed the European Commission and the EU institutions but also relevant national competent authorities more broadly, the particularities of homeopathic medicinal products, as well as their effectiveness and safety and the different national approaches in the EU Member States.

Results

Ultimately our strategy allowed our client to enter into a constructive dialogue with relevant national authorities. Alber & Geiger followed the maxim that sometimes less regulation is more, reflecting the priorities of our clients’ industries.

Challenge

The European Commission initiated anti-dumping proceedings concerning imports of polyvinyl alcohol (PVA) originating from China. The investigation on the dumped PVA was worth more than $33 million. Solutia, a U.S. Fortune 500 firm and a Monsanto spin off, was one of the parties concerned by this investigation. Solutia relied heavily on PVA to produce polyvinyl butyral (PVB), a material used in glass, construction and auto industries. With only 5-months’ notice, Solutia sought Alber & Geiger’s help to avoid import duties on PVA.

Strategy

Alber & Geiger produced a narrative that included an understanding of the Chinese economy and the PVA market in China. Our message was strongly embedded in the European Commission’s approach to trade and competition law, while taking into account the global political consensus on Chinese PVA dumping. More concretely, we put forward arguments that the dumping was a natural consequence of China’s macro-economic situation and production pressures.

Our team demonstrated that other market factors had contributed to the EU economic injury. We argued that the European Commission had not shown a causal link between the detriments suffered by the EU market and dumped imports from China. Moreover, our message cast doubt on the way the European Commission had defined the market of PVA in light of the broader range PVA uses.

Results

Alber & Geiger’s lobbying activity led to the European Commission revising its preliminary duties decision on PVA imports. As we had argued, the European Commission concluded that there was no evidence that would link dumping and injury. The tariffs were lifted. Solutia’s profitability and position on the global market remained intact.

Challenge

INTCO is a Chinese company and the world market leader in medical disposable gloves. The company plays a central role in securing reliable, high-quality medical supplies for hospitals, healthcare providers, and patients worldwide.

The European Commission considered applying the International Procurement Instrument (IPI), which could restrict third-country suppliers’ access to EU public tenders. For INTCO, this risked exclusion from medical procurements across the Union—threatening supply continuity, competitive pricing, and Europe’s preparedness for future health emergencies, including the next pandemic.

Strategy

Alber & Geiger engaged the European Commission and the European Parliament, and coordinated with key Member States to prevent discriminatory treatment under the IPI. We made the cross-institutional case that open competition in medical tenders strengthens supply resilience, affordability, and strategic autonomy, safeguarding the Union’s readiness for the next pandemic.

Results

INTCO preserved full access to EU procurement and maintained its ability to compete in medical tenders across Europe. European hospitals retained reliable and affordable access to essential disposable gloves and supplies—reinforcing the Union’s health security and preparedness for future crises.